Research News for March 2008
11–19 of 19 articles
-
Mouse Study Finds Gene That Signals Breast Cancer to Grow and Spread
Researchers have found a gene in mice that appears to trigger the spread of mouse breast cancer cells.
-
Femara After Five Years of Tamoxifen Reduces Recurrence Risk
Taking the aromatase inhibitor Femara (chemical name: letrozole) after taking tamoxifen for 5 years reduced the risk of the breast cancer coming back (recurrence), compared to not taking Femara after tamoxifen, even when Femara was started up to 7 years after tamoxifen.
-
Drinking Alcohol While Taking Hormone Replacement Therapy Increases Risk
Drinking alcohol while taking hormone replacement therapy (HRT) dramatically increases breast risk, according to a Danish study.
-
Yoga of Awareness Helps Ease Hot Flashes
A small study found that a particular yoga program helped ease menopausal symptoms in women treated for early-stage breast cancer.
-
Link Between Risk, Anti-Inflammatory Medicines Unclear
A review of research results suggests an association between nonsteroidal anti-inflammatory (NSAID) medicines and breast cancer risk.
-
Herceptin with Dose-Dense Chemo Reduces Risk of Heart Problems
A small study has found that when Herceptin (chemical name: trastuzumab) was given in combination with dose-dense chemotherapy, the risk of heart problems from Herceptin was lower than when Herceptin was given with a routine schedule of chemotherapy.
-
Study Suggests Link Between Gestational Diabetes and Lower Risk
A new study has found a possible link between breast cancer risk reduction and gestational diabetes.
-
High Estrogen Levels May Lead to Recurrence
Women diagnosed with early-stage breast cancer that came back (recurred) had higher blood estrogen levels than women diagnosed with early-stage breast cancer that didn't come back.
-
Women’s Health Initiative Study Suggests Women Who Took Combination Hormone Replacement Therapy Have Higher Risk of Breast Cancer
Results from the Women's Health Initiative show that women who took combination hormone replacement therapy (HRT) were more likely to be diagnosed with breast and lung cancer after they quit taking the HRT than women who got a placebo.
11–19 of 19 articles
